Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors
17 January 2018 - 12:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE:CRL) today
announced the appointment of Jean-Paul Mangeolle, former President
of AB SCIEX, to its Board of Directors. Mr. Mangeolle’s extensive
experience leading global life science and bioscience companies,
with a specific focus on high-end instrumentation, will provide
Charles River with a unique combination of expertise. As a member
of the Board, he will serve on the Audit and Compensation
Committees.
“Mr. Mangeolle’s background leading global organizations and
expanding into key international markets will enhance the expertise
of Charles River’s Board and play a valuable role as we
strategically expand Charles River’s unique portfolio of
early-stage drug research products and services,” said James
C. Foster, Chairman, President and Chief Executive Officer of
Charles River. “His extensive experience with the conception,
design, manufacture, and marketing of high-end instrumentation will
be particularly helpful as we continue to build our Microbial
Solutions business.”
Mr. Mangeolle has more than 35 years of experience in life
science and bioscience on a global scale. He has extensive
experience building teams and profitable businesses across the
globe in multiple market segments, including biotechnology and
pharmaceutical companies, academic research laboratories,
microelectronics manufacturing, and OEM companies. He retired
recently from AB SCIEX (an operating company of Danaher Corp.),
where he had held the position of president since 2014. In that
role, he was responsible for Sciex’s and Phenomenex’s global
operations. Previously, he was Executive Vice President for the
Process Solutions Business Unit of Merck KGaA Millipore. Mr.
Mangeolle spent more than 25 years with Millipore in progressively
larger roles, culminating in the role of President, Bioprocess
Division, where he was also a member of the Corporate Executive
Committee and an elected corporate officer.
“I am pleased to join Charles River’s Board of Directors and
look forward to contributing to the future success and growth of
this recognized global leader in early-stage drug discovery and
development,” said Mr. Mangeolle. “In particular, I am looking
forward to providing strategic counsel to Charles River’s Microbial
Solutions business, drawing on my manufacturing experience to
support its future growth.”
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“may,” “estimate,” “plan,” “outlook,” and “project,” and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. Forward
looking statements include statements in this press release
regarding future demand for drug discovery and development
products, as well as growth of the Microbial Solutions business,
and the specific contributions of members of Charles River's Board
of Directors. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of
risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated
or implied by the forward-looking statements. A further description
of these risks, uncertainties, and other matters can be found in
the Risk Factors detailed in Charles River's Annual Report on Form
10-K as filed on February 14, 2017, as well as other filings
we make with the Securities and Exchange Commission. Because
forward-looking statements involve risks and uncertainties, actual
results and events may differ materially from results and events
currently expected by Charles River, and Charles River assumes no
obligation and expressly disclaims any duty to update information
contained in this news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180116005470/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2024 to May 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2023 to May 2024